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ADRIAMYCIN, VINBLASTINE, AND MITOMYCIN C (AVM) VERSUS 
ADR IAMYCIN ALONE IN THE TREATMENT OF 
METASTATIC BREAST CANCER 
Cristina Bengoa-Becerra 
1988 
Fifty-four patients with metastatic breast carcinoma refractory to 
conventional chemotherapy entered this prospective and randomized study. 
One group was treated with Adriamycin 60 mg/m^ IV every 3 weeks. The 
other group received Adriamycin 30 mg/m^ IV and Vinblastine 6 mg/m^ IV 
every 4 weeks and 10 mg/m^ IV Mitomycin C every 8 weeks (AVM). Drug 
dosages were modified if hematologic toxicity occurred. Responses 
occurred in 15% (4/26) of the Adriamycin patients and 29% (8/29) of the 
AVM patients (p>.2). The median time to disease progression was 3.8 and 
5.9 months respectively (p = .03). Median survival time was 7.9 and 9.0 
months respectively (p = .35). Toxicity was acceptable in both groups 
and primarily hematologic. No cardiac toxicity was seen. This 
combination of Adriamycin, Vinblastine, and Mitomycin C appears to be an 
acceptable alternative to Adriamycin alone for second-line chemotherapy 
of metastatic breast cancer. 
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PART ONE: CHARACTERISTICS 
INTRODUCTION 
The breast is the most common site of cancer among U.S. women. It 
has been estimated that the probability of developing breast carcinoma is 
9.1%; that is, 1 in every 11 women will develop cancer of the breast 
during their lifetime*. Currently, the overall incidence is 72 in 
100,000 women^. 
In general, the natural history of the disease is extremely 
variable. A few patients will have a rapid fulminating illness; while 
others will have a slower more indolent course. 
SITES OF RECURRENCE 
The current treatment for primary breast cancer is surgery with 
modified radical mastectomy being the most cornnon. In addition to 
surgery, a number of patients also receive adjuvant treatment with 
radiation therapy, chemotherapy and/or hormonal therapy. Many patients 
with early-stage breast cancer are being treated with lumpectomy, lymph 
node disection and adjuvant radiation therapy as an alternative to 
radical surgery**. 
Unfortunately, these procedures do not offer a definite cure for all 
patients. More than 50% of patients have recurrence of their disease in 
local and/or distant sites. Most of these patients relapse within 18-24 
months after their mastectomy-*. The fact that patients might be disease- 
free at 5-10 years after their initial treatment does not imply cure. 





The incidence of 1ocal/regional recurrence is approximately 10- 
20%3>4. Most recurrences occur within two years of initial surgery^. 
Local recurrence has been defined as recurrence in the skin or 
subcutaneous tissues of the chest wall within the boundaries of a 
previous lumpectomy/mastectomy. Regional recurrence is defined as 
lesions in lymph node-containing areas of the internal mammary chain, the 
axilla, and the supraclavicular area. Both local and regional recurrence 
present serious problems because, if left untreated, they tend to grow, 
ulcerate, and spread^. 
The prognosis of 1 oca 1 / reg i on a 1 disease is not very good. 
Approximately 50% of patients have distant metastases simultaneously with 
local recurrence^. Even of those patients with disease initially limited 
to local/regional sites, 80-90% relapse at distant sites within the chest 
wall. Those patients with recurrence in the axilla tend to do better^. 
Distant Metastasis 
The most common sites of distant metastasis are bone, lung 
(including pleura), brain, and liver. Approximately 85% of patients who 
die of metastatic breast cancer have bone metastases. These usually 
present with pain and are best diagnosed by x-ray and bone scans 1. 
Metastasis to the lung may present with cough, hemoptysis and/or 
dyspnea. The latter is usually due to obstruction and atelectasis caused 
by endobronchial lesions. They can occur as discrete coin lesions which 
are easily diagnosed by x-ray or may be adjacent to the hilum or 
mediastinum, often associated with infection or pneumothorax. The latter 
are easily missed by chest x-ray and are best diagnosed by CT scan. 
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Bronchoscopy is also employed to evaluate obstruction. In addition, 
pleural effusions are many times the initial manifestation of 
intrathoracic metastatic disease^*^. 
The central nervous system (CNS) is also a frequent site of 
disseminated disease. Ten percent of stage IV breast cancer patients 
have CNS metastases which include lesions to the brain and/or meninges. 
These occur more frequently in patients with large primary tumors and/or 
axillary node metastasis. They are also more comnon in patients younger 
than 60 years and/or less than five years postmenopausal^. Brain 
metastates, which may be detected by CT scan, are usually multiple and 
occur in the distribution of the middle cerebral artery. The parietal 
lobe is most commonly affected. Usually they present with headache, 
motor dysfunction, and impaired mentation"7. 
Finally, another common site of visceral metastases is the liver. 
Hepatic metastases can present with pain, tenderness to palpation, 
hepatomegaly and/or hepatic failure. Unfortunately up to 60% of livers 
containing metastases are not palpable; and so, they are best evaluated 
by technetium liver scan and liver function tests. Nonspecific 
abnormalities detected by liver scan are then further evaluated by 
ultrasound (U/S) or CT^.IO. 
PROGNOSTIC FACTORS 
A number of clinical, pathological, and biochemical variables have 
been identified as having prognostic significance in both the likelihood 
of first recurrence and the subsequent course of metastatic disease. The 
following prognostic factors have been shown to determine the likelihood 
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of initial recurrence and survival: tumor size and location, number and 
level of axillary nodes involved, histologic type and grade, and 
biochemical parametters such as estrogen receptors (ER) and to a lesser 
extent, progesterone receptors (PR)^. Another variable which has been 
shown to favorably affect prognosis is adjuvant therapy^. Once the 
patient presents with metastatic disease, the indicators of prognostic 
value have been found to be: disease free interval (DF1), types and 
number of metastatic sites, and response to initial therapy^,14. 
Prognostic Indicators of Disease Recurrence 
In terms of tumor size, it has generally been determined that the 
larger the tumor, the worse the prognosis1^*16. However the number of 
axillary nodes involved with tumor appears to be more important. For 
example, in 1.0-1.9 cm tumors, the 5 year recurrence rate with negative 
vs. positive nodes has been quoted as 13% and 53% respectively, whereas 
in 3.0-3.9 cm tumors the numbers are 28% and 64%^. Location of the 
tumor within the breast area also appears to be associated with response 
to therapy. Nemoto, et al^ reported that tumors in the medial half of 
the breast had slightly higher "cure" rates than those in the lateral 
half. 
One of the most important clinical factors in determining prognosis, 
as already mentioned above, is the number of positive axillary 
nodes^* 15,16. With zero positive nodes, the 5 year recurrence rate is 
18-21%3,15,16^ ancj the 5 year survival is 72-76%15,16. With one to three 
positive nodes the 5 year recurrence rate is approximately 50%3>15, anc) 
the 5 year survival is 62%15. Unfortunately, these numbers drastically 
plummet with four or more positive nodes, such that the five year 
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recurrence rate is 81% and the 5 year survival is 31%^. Robbins*' 
divides prognosis into three groups based on the location of involved 
axillary nodes: level I nodes - those lateral and inferior to the 
pectoralis major muscle - are associated with a 10 year survival of 41%; 
level II nodes - those behind the pectoralis minor muscle - are 
associated with a 10 year survival of 30%; and level III nodes - those 
medial and superior to the pectoralis minor muscle at the apex of the 
axilla - are associated with a 10 year survival rate of 15%. 
Pathologic factors have also been identified as prognostic 
indicators . The two most important ones appear to be histologic type 
and grade of tumor. Though of lesser significance, other histogic tumor 
features, such as lymphatic and blood vessel invasion and presence of 
tumor necrosis, have been associated with a worse prognosis. 
The most coimon histologic type of breast cancer is infiltrating 
ductal, which represents 70%^a of all infiltrating carcinomas. The 
prognosis is variable and depends on grade which will be discussed later. 
Medullary carcinoma has been said to account for 6%*^ of all 
invasive carcinomas. The prognosis depends on the amount of lymphoid 
infiltrate. The variant called medullary carcinoma with lymphoid 
infiltration has an incidence of 5%*^. It is said to have a better 
prognosis than infiltrating ductal carcinoma even in the presence of 
axillary metastases. The 10 year survival for this variant is 84%^. 
The colloid or mucinous type tends to occur in older women and grows 
slowly over the course of many years. It represents approximately 3%*^ 
of all invasive breast cancers. Its prognosis is much better than 
infiltrating ductal or mucinous combined with other types. Lymph node 

6 
metastases are infrequent^. 
Infiltrating lobular accounts for 5-14%*d of all infiltrating breast 
carcinoma. It tends to occur bilaterally approximately 20% of the time 
and also has a high incidence of multicenticity. Prognosis is similar to 
that of infiltrating ductal with 5 and 10 year survival rates of 70% and 
57%, respectively, versus 73% and 46% for infiltrating ductal^*. 
The tubular type represents 7% of all invasive carcinomas and 
carries an excellent prognosis**. 
Histologic grade, which depends on degree of tubule formation, size 
of cells, nuclear pleomorphism, degree of hyperchromatism, and number of 
mitotic figures is another variable of prognostic significance**. For 
the most part. Grade III (high grade) tumors are associated with earlier 
more frequent recurrence and lower 5 year survival than Grade I (low 
grade) tumors. However, the stage of the tumor also determines survival; 
such that, a high grade stage I tumor has a higher ID year survival rate 
(62%) than a low grade Stage III tumor (53%) (Table 1)^. 
Biochemical markers, such as the concentration of estrogen* *»23-24 
and progesterone^^ receptors in the tumor, are also said to be 
prognostic indicators of recurrence. ER positive tumors (concentration 
>10 pmol g"*) are associated with a longer disease-free interval and a 
lower recurrence rate than ER negative tumors **» ^*^4. PR positive 
tumors (concentration >10 pmol g-*) are also associated with a favorable 
prognosis, longer disease free interval**, and lower probability of 
distant metastasi s7 »25. Pichon and coworkers*^ reported that patients 
with PR positive tumors were 3.6 times less probable to develop distant 
metastasis than patients with PR negative tumors. They also demonstrated 
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that there was an inverse relationship between PR, concentration ([PR]), 
and the frequency of metastasis. However, the incidence of local 
recurrence does not appear to be affected by [PR]. 
Finally, adjuvant therapy has been shown to improve prognosis, 
particularly disease-free (DFS) and overall survival (OS)^. A review by 
Bonadonna and Valagussa^, which included 2,213 patients, revealed a 
significant increase in overall survival for patients treated with 
adjuvant chemotherapy regimens versus control (no systemic therapy). It 
appears that this difference is mostly seen in premenopausal patients 
with one to three positive axillary nodes. In this subset, adjuvant 
chemotherapy has been shown to prolong both disease-free and overall 
survival. In the past, data for postmenopausal patients have failed to 
demonstrate a clear advantage of adjuvant chemotherapy over control. 
However, the 5 year results of a recent study by Brambilla and 
coworkers^ employing sequential CMFP and AV in 140 postmenopausal 
patients showed prolonged disease-free and overall survival for a subset 
of patients with one to three positive lymph nodes over control (i.e., OS 
- 87% versus 73% and DFS - 76% versus 60% for treated and control groups, 
respectively). 
Adjuvant endocrine therapy has not proven to be as successful as 
chemotherapy^. In premenopausal patients, most studies have failed to 
demonstrate an increase in disease-free and/or overall survival with 
oophorectomy in treated patients versus control. Adjuvant tamoxifen has 
been shown to increase disease-free survival in a subset of post¬ 
menopausal patients with positive estrogen receptors and positive 
axi 1 lary nodes^ . 

Prognostic Indicators for Course of Metastatic Disease 
With respect to prognosis after the first relapse has occurred, 3 
sets of variables have been identified: Disease-free Interval (D F1), 
types and number of metastatic sites, and response to therapy ,14. 
Overall, the shorter the DPI (time from initial diagnosis to first 
relapse) the shorter the survival. 
Cutler et al^ evaluated yu patients and divided them into 4 groups 
depending on their DPI: 1 year, 1-2 years, 2-b years, and >b years. 
They found the median survival to be 7 months, 12 months, lb months, and 
2b months, respectively. 
Pei and associates^ studied median survival in 40b patients with 
respect to types of metastatic sites. Patients were divided into four 
categories. Category A consisted of patients with pure local/regional , 
local type with pleural involvement, and pure osseous metastases. These 
patients had the better prognosis with a median survival of bU-b8 months 
after diagnosis and 27 months after first relapse. Category B was made 
up of those patients with pure visceral metastasis. Median survival, in 
this group was 40 months after diagnosis and 23 months after first 
relapse. Category C consisted of patients with mixed sites of 
metastasis. The median survival, for these patients, was 33-43 months 
after diagnosis and 17 months after first relapse. Patients with the 
worse prognosis were those with locally inoperable disease (Category D). 
Their median survival was 19 months after diagnosis. Survival with 
respect to number of metastatic sites was evaluated by Cutler et al. . 
They found that median survival ranged from 18-24 months with only one 
site involved, 9-12 months with two to three sites involved, and 6-10 
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months with four or more sites involved. Overall, bony metastases are 
found to progress little, if any; visceral metastases, particularly those 
with mainly lung involvement, have a limited tendency to spread; and 
local/regional metastases have a progressive course^. 
The other parameter said to influence survival in patients with 
metastatic disease is response to treatment. Fei and associates^ 
reported that those patients who have a complete response or a partial 
response greater than 501 had a longer median survival than those with a 
partial response less than 50%, no change, or disease progression. 
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PART TWO: ENDOCRINE THERAPY 
The initial treatment of patients with metastatic breast carcinoma 
usually consists of endocrine therapy. The following have been employed 
with varying degrees of success: endocrine ablative procedures 
(medical/surgical ), tamoxifen, progestins, and recently danazol . 
Furthermore, the use of these agents in combination versus sequentially 
has also been evaluated. 
ENDOCRINE ABLATIVE PROCEDURES 
In the past, endocrine ablative procedures have been extensively 
employed in the treatment of patients with metastatic breast cancer. 
Adrenalectomy (medical/surgical) and hypophysectomy have been utilized in 
postmenopausal patients and oophorectomy has been the preferred treatment 
for premenopausal pati ents^,29. 
The response rates obtained in postmenopausal patients with such 
surgical approaches ranges from 25-57%^0-33^ Forest^ reported pooled 
data from four studies including 615 patients who underwent 
hypophysectomy. Response rates ranged from 22-35%. Pearson and 
associates^ studied the results of hypophysectomy in 218 patients with 
metastatic breast cancer using transfrontal craniotomies. They reported 
results in 109 patients with response rate of 50%, 35% of these lasting 
up to 6 months or longer. However, they found the procedure to be 
associated with serious morbidity: serious visual loss (2 patients), 
visual field defects (7 patients), neurological involvement (3 patients), 
and pathological fracture of the femur (1 patient). Edelsyn and 
coworkers^ examined the benefits in patients treated with hypophysectomy 
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plus an Yttrium implant. They reported a response rate of 57% versus 24% 
when patients were treated with surgery alone. With respect to surgical 
adrenalectomy, Daincoff and coworkers22, in a study with 415 patients, 
had a response rate of 28% with a 5 year survival rate of 12.5%. They 
also found that patients with metastases at skeletal, cutaneous, pleural, 
and pulmonary sites had a longer survival than those with metastases in 
brain or liver. 
Bilateral oophorectomy has been employed in premenopausal patients 
with response rates of approximately 30%. Patients with metastases at 
skeletal, soft tissue or pleural sites are more likely to respond than 
those with metastases in brain or liver. Side effects associated with 
this procedure are mainly menopausal symptoms which are quite acceptable 
for those patients who respond28. 
Medical adrenalectomy with the agent aminoglutethimide (AG) given 
with steroid replacement is used as an alternative to surgical procedures 
in postmenopausal patients with metastatic breast cancer28. 
Wells and associates2^ used a regimen of AG 1,000 mg per day and 
either Dexamethasone 2-3 mg per day, or Hydrocortisone 40-60 mg per day 
in 50 patients with advanced breast cancer. They obtained a response 
rate of 38% with a median duration of response of 18.05 months. 
Furthermore, it has been shown that ER status is a useful predictor 
of response to therapy with ami nog 1utethimide28»28. Santen and 
coworkers28 studied 69 patients, all of which were ER positive or ER 
unknown. They employed a regimen of AG 250 mg twice a day for the first 
two weeks and 250 mg four times a day therafter. They reported a 53% 
remission rate in 40 patients treated with aminoglutethimide. Lawrence 
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and associates33 reported a 50% remission rate in 38 patients with ER 
positive tumors versus 14% in 7 patients with ER negative tumors. 
Toxicities associated with AG therapy are varied. One study with 50 
patients found the main side effects to be: lethargy (41.5%) and skin 
rash (36%). No chronic toxicities were encountered3^. Another study 
with 69 patients found both acute and chronic toxicities. Acute 
toxicities which developed during the first six weeks of treatment were: 
lethargy (48%), drug rash (33%), orthostatic dizziness (20%), ataxia 
(10%), and drug fever (2.5%). Chronic toxicities which appeared or 
continued beyond six weeks of therapy were: lethargy (10%), orthostatic 
dizziness (12%), depression (10%), hypothyroidism (5%), ataxia (2.5%), 
blurred vision (2.5%), and nausea/vomiting (2.5%)33. 
With respect to more severe toxicities, Santen and coworkers33 
report that episodes of leukopenia, thrombocytopenia, or pancytopenia 
occured in 4% of the 639 patients reported in Ciba-Geigy records. 
Furthermore, one episode of pancytopenia complicated by bleeding and gram 
negative septicemia which resolved promptly after stopping AG therapy has 
been reported3'7. 
Medical adrenalectomy with AG has been compared to surgical 
endocrine ablative procedures by various groups of investigators. Harvey 
and associates33, in a randomized clinical trial with 35 patients, 
compared medical adrenalectomy with AG to transfenoidal hypophysectomy. 
They obtained remissions in 10 of 21 patients (47%) with a median 
duration of 11.5 months in the AG treatment group. In the 
hypophysectomized group only 3 of 14 patients (21%) showed remission. 
The median duration for these patients was 4-6 months. Santen and 
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coworkers^ reported a response rate of 53% with AG versus 45% with 
surgical adrenalectomy. 
In view of these reports and the decreased toxicity of AG as com¬ 
pared to the morbidity and mortality associated with surgical procedures, 
it appears that AG is a preferable alternative to surgery in endocrine 
suppression and treatment for postmenopausal patients with advanced 
breast cancer. 
TAMOXIFEN 
The introduction of the antiestrogen tamoxifen (Nolvadex) is one of 
the most important recent advances in the treatment of advanced breast 
cancer. Many clinical trials have been done in order to try to establish 
the efficacy of this agent^. Morridsen and associates^ reviewed pooled 
data from 19 studies involving 1122 patients. Reported response rates 
vary from 16-52%; the overall rate was calculated as 32%. The median 
duration of response ranged from 6.7-17.5 months. They also found the 
incidence of side effects to be low. With respect to menopausal states, 
response rates were found to be similar in premenopausal and 
postmenopausal patients; i.e., 31% and 32%. However, those patients 
which were within five years of menopause (perimenopausal) had a lower 
response rate (23%). 
Three clinical studies address the efficacy of tamoxifen in a group 
of premenopausal patients. Hoogstraten et al.41 obtained responses in 14 
of 138 patients (37%) using a dose of 10 mg twice a day. Manni and 
associates^ showed remissions in 5 of 11 patients (45%) with a median 
duration of 19+ months. They employed a dose of 40-120 mg per day. 
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Prichard and coworkers1^ demonstrated responses in 13 of 42 patients 
(32%) with a median duration of 289+ days using a dose of 20 mg twice a 
day. Furthermore, they showed that patients with ER positive tumors had 
a response rate of 44% versus 11% in those patients with ER negative 
tumors. Thus, ER status appears to be a good predictor of response to 
tamoxifen. 
Morridsen and associates^ also evaluated response according to 
sites of metastatic disease. They found that soft tissue metastases were 
more responsive (response rate: 138 of 392 patients - 35%) to tamoxifen 
treatment than bone (response rate: 60 of 238 patients - 25%) or visceral 
metastases (response rate: 62 of 214 patients - 29%). Furthermore, ER 
status was a positive predictor of response. Response rate was 49% in 
patients with ER positive tumors versus 7% in patients with ER negative 
tumors. 
Side effects associated with tamoxifen therapy have been found to be 
not 1 i fe-treateni ng and the incidence reported is extremely low. In 
Morridsen's review^ of 1122 patients reported side effects were as 
follows: mild nausea and/or vomiting - 107 patients (1%), hot flashes- 
94 patients (0.8%), transient thrombocytopenia - 52 patients (0.5%), 
increased tumor pain and inflammation - 20 patients (0.2%), and 
hypercalcemia - 11 patients (0.1%). 
The recommended dose of tamoxifen is 20 mg per day^. Various 
investigators have evaluated the efficacy of employing higher doses (30- 
90 mg daily). Ward4^1, in a randomized clinical trial with 68 patients 
found no difference in employing a dose of 10 mg twice a day versus 20 mg 
twice a day; response rates were 36% and 40% respectively. Steward and 
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associates4*3 treated 25 patients who had had disease progression on 10 mg 
twice a day (9 of whom had previously responded) with 20 mg twice a day. 
They did not observe any responses. Morridsen and coworkers4^ reported 
no remissions in 19 patients treated with a dose of 30 mg daily and one 
partial response after the dose was increased to 90 mg daily. On the 
basis of these studies, it appears to be of no benefit to employ a dose 
greater than the conventional one. 
The efficacy of tamoxifen has been compared to that of 
est rogen s4 ^»4^, androgens 4^, and the endocrine ablative procedures 
(medi cal 50,51 anc| surgi cal ^2,53). 
Tamoxifen has been found to be as efficacious or better than 
est rogens4^»4^ and androgens4^. Lipton and associates4'7 employed a 
regimen of diethystibestrol (DES) 5 mg three times a day versus tamoxifen 
10 mg two times a day in 143 postmenopausal patients, none of which had 
had prior hormonal treatment. They showed a response rate of 41% with 
DES versus 33% with tamoxifen. This difference was not found to be 
statistically significant. However, they found tamoxifen to have less 
side effects and decreased overall toxicity than DES. Another estrogen, 
ethinyl estradiol (EE2) was compared to tamoxifen in a study by Beryl and 
associates4^. They evaluated a regimen of EE2 0.3 mg per day given with 
chlorothiazide, to prevent fluid retention, versus tamoxifen 20 mg twice 
a day in 59 postmenopausal patients, 12% of which had had prior hormonal 
therapy. Response rates (EE2 - 31%; tamoxifen - 33%), median duration of 
response (EE2 - 12 months; tamoxifen - 11 months), and median survival 
time (EE2 - 31 months, tamoxifen - 25 months) were similar for both 
groups of patients. Side effects with EE2 were more serious than with 
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tamoxifen. Both groups of investigators concluded that tamoxifen should 
be a drug of choice over estrogens in the treatment of postmenopausal 
patients with metastatic breast cancer because it leads to similar 
percentage of remissions with less toxicity. The latter issue, 
particularly fluid retention with associated congestive heart failure is 
of particular concern in elderly patients or those with extensive lung 
metastases. 
Androgens have been found to cause remissions in 10-20% of patients 
with median survival of 19-23 months for responders. Response rates are 
higher with increasing age and time elapsed after menopause^. 
Westenberg and coworkers^ compared the efficacy of androgens, using 
f 1 uoxymesterone 10 mg twice a day, to that of tamoxifen, using a 20 mg 
dose twice a day. They reported remissions in 24 of 37 patients (30%) in 
the tamoxifen treatment group versus 15 of 42 patients (19%) in the 
fl uoxymesterone treatment group. Survival and time to disease 
progression were also significantly longer with the tamoxifen than with 
the fluoxymesterone group. Furthermore, tamoxifen was not associated 
with the side effects of androgen therapy: virilization, acne, 
hirsutism, and hypercal cemi a; and therefore, should be a preferred 
treatment over androgens for patients with advanced breast cancer. 
Various investigators have compared tamoxifen with endocrine 
ablative procedures. Kiang et al. -jn a randomized clinical trial with 
a crossover phase compared tamoxifen using a dose of 20 mg per day versus 
hypophysectomy using a transphenoidal approach. They reported response 
rates of 71% (tamoxifen group) versus 67% (hypophysectomy group) with 
median duration of response of 12.5 months, and 13.0 months respectively. 
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Nemoto and associates33 obtained response rates of 52% with adrenalectomy 
versus 35% for tamoxifen, but this difference was not statistically 
si gnificant. 
Two studies39*3^ compare medical adrenalectomy with 
aminoglutethimide versus tamoxifen. Smith and associates38 employed a 
regimen of tamoxifen 10 mg twice a day for the first 2 weeks then four 
times a day with hydrocortisone 20 mg per day in 117 patients. They 
obtained a response rate of 30% for both treatment groups. Also, no 
significant difference in survival (15 months for both groups) or 
duration of response was found. Ami nogl utethimide, however, had a 
significantly greater remission rate in bone metastases (35%) than 
tamoxifen (17%). Of note, 7 of 97 patients in the AG treatment group had 
to discontinue therapy because of toxicity, whereas none of the 95 
patients receiving tamoxifen had to do so. Upton et al.^1 employed the 
same regimen except for a higher hydrocortisone dose of 100 mg per day in 
divided doses during the first two weeks, then 40 mg per day in divided 
doses thereafter. They also found similar response rates for both 
groups: 38% for the tamoxifen group and 36% for the AG group. 
Furthermore, they too found higher response rates in bony metastases but 
these were not statistically significant. It appears that because of its 
reduced toxicity, tamoxifen would be the treatment of choice; however, AG 
should be considered in patients with heavy burden of bone metastasis28. 
PR0GESTINS 
Progestins have also been employed in the treatment of metastatic 
breast cancer patients28*39. In clinical studies with mostly 
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postmenopausal patients reported response rates range from 10-20%. These 
numbers are substantially lower than those obtained with other endocrine 
agents^. A review by Lober and coworkers55 reports an average response 
rate of 32% with a median duration of response of 14-52 weeks. Higher 
remission rates were seen in soft tissue and bone metastases (48% and 
46%, respectively) versus visceral metastases (17%). Side effects were 
all found to be mild, not requiring dose modification. 
Rubens and coworkers56 found a 25% remission rate with a median 
duration of response of 3.5 months using norethindrone acetate 20 mg 
three times a day. They obtained best responses in cutaneous metastases. 
Visceral metastases were found to be resistant, for the most part. 
Edelsyn et al5^ showed a higher response rate (41%) with a lower dose (10 
mg four times a day) of the same agent. Again, metastases in soft tissue 
were found to have a higher remission rate than bone or visceral 
metastases. Another progestin, megestrol acetate was employed by 
Alexi va-Figush and associates 5^ in a clinical trial involving 160 
patients. They obtained a response rate of 29%. Soft tissue metastases 
were found to be the most responsive lessions with a remission rate of 
35%; whereas visceral metastases were the least responsive with a 
remission rate of 25%. Using medroxyprogesterone acetate response rates 
of 40% have been reported with doses of 500-1000 mg per day IM. These 
doses are markedly higher than the previous conventional dose of 40-400 
mg per day IM which produce a response rate of 17%5^. 
NEWER AGENTS: DANAZ0L 
Other endocrine agents have been studied in the treatment of 
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patients with advanced breast cancer without much success. One such 
agent, danazol, which is employed in the treatment of benign breast 
disease, was studied by Coombes and coworkers6*"1. They used a regimen of 
100 mg three times a day later increased to 200 mg three times a day in 
most patients. Thirty-seven of the 41 patients in the study were 
postmenopausal. Response rates obtained for these patients were low 
(7 of 37 patients - 18%) and side effects were seen in 22% of the 
patients, mainly at higher doses (600 mg per day). The 4 premenopausal 
patients also included in the study showed no objective responses. 
COMBINATION VERSUS SEQUENTIAL TREATMENT 
Combination endocrine treatment has not been studied as extensively 
as combination chemotherapy22*39,61. Staquet6! cites a review of 
Macaulay and Smith6-*- of 13 randomized trials comparing combination 
endocrine treatment with single agent endocrine therapy. All of the 
studies failed to demonstrate a higher response rate or survival of 
combination over single agent. 
Four randomized clinical studies showed combination regimens 
including tamoxifen to be therapeutically superior to tamoxifen as a 
single agent. A study by Powles and associates62 included 222 patients 
randomized to a combination of tamoxifen 10 mg twice a day, danazol 100 
mg three times a day, and aminoglutethimide 250 mg three times a day 
(TAD) versus tamoxifen as a single agent using a dose of 10 mg twice a 
day. The combination TAD had a higher response rate (43%) than tamoxifen 
alone (31%). Torrney and coworkers62 compared a combination of tamoxifen 
(2-100 mg/m2 twice a day) and f1uoxymesterone (7 mg/m2 twice a day) 
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versus tamoxifen alone (2-100 mg/m^ twice a day) in 108 postmenopausal 
patients. They obtained remission rates of 38% with a time to treatment 
failure of 180 days for the combination which were significantly higher 
than those obtained with tamoxifen alone (response rate: 15% with a time 
to treatment failure of 64 days). Survival, however, was not 
statistically significantly higher. Stewart et al64 showed statistically 
significantly higher response rates with a combination of tamoxifen 10 mg 
twice a day and prednisone 5 mg twice a day (36% with a median survival 
of 21 months) than with tamoxifen 10 mg twice a day as a single agent 
(13% with a median survival of 12 months) in a study with 145 
postmenopausal patients. Lipton and coworkers5! studied a combination of 
tamoxifen 10 mg twice a day and aminoglutethimide 125 mg four times a day 
with hydrocortisone 100 mg per day in divided doses for the first two 
weeks, and then ami nogl utethi mi de 250 mg four times a day with 
hydrocortisone 40 mg per day in divided doses, versus tamoxifen 10 mg 
twice a day as a single agent. Response rates obtained in the 55 
postmenopausal patients were higher with the combination regimen (37%) 
than with tamoxifen alone (26%). 
In addition to treatment with combination endocrine regimens the use 
of these agents sequentially has also been evaluated. It appears that 
the sequential use of endocrine agents increases the chances of second- 
line responses. Not only may it produce responses in those patients who 
have responded and subsequently progressed on a previous treatment, but 
also it may induce remissions in patients who have failed initial 
treatment. 
Kiang and associates5^ showed the sequence hypophysectomy-tamoxifen 
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to have a higher response rate (57%) versus tamoxi fen-hypophy sectomy 
(22%). Smith and coworkers^ found AG to be effective in 4 of 6 patients 
(67%) who have relapsed on tamoxifen and on 5 of 34 patients (15%) who 
have failed to respond. However, the sequence AG-tamoxifen failed to 
induce responses in any of the 4 patients who had previously responded 
and induced only 2 responses in 31 patients who had previously failed. 
The sequence tamoxi fen-AG had a markedly higher overall response rate 
(9 of 40 patients - 23%) than the sequence AG-tamoxifen (2 of 35 patients 
- 6%). The authors suggested that the lack of complete cross-resistance 
between these two drugs may be related to their different mechanisms of 
action. 
In premenopausal patients, the sequence tamoxifen-oophorectomy with 
continuing tamoxifen therapy has been studied by three groups of 
investigators with conflicting results. Pritchard et al.^3 had 6 
responses in 8 patients who had previously responded to tamoxifen and 
subsequently progressed but no responses in any of the 13 patients who 
had failed tamoxifen treatment. Their overall response rate was 29%. 
Manni and associates^ with a smaller number of patients had 1 response 
in 2 patients who had previously responded, but no responses in any of 
the 3 patients who had failed. Their overall response rate was 20%. 
Results obtained by Hoogstraten et al are completely different. None 
of the previous 14 patients who had responded to tamoxifen treatment had 
remission with oophorectomy plus tamoxifen; whereas 5 of the 22 patients 
who had previously failed tamoxifen achieved remissions. Their overall 
response rate was lower than in the previous two studies (14%). The 
authors hypothesized that the initial dose of tamoxifen might have been 
too low to block all of the estrogen receptors given that these patients 
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are still premenopausal. Furthermore, ovarian castration by eliminating 
the main source of estrogen will allow the antiestrogen source of 
tamoxifen to be more efficacious. 
SUMMARY 
In summary, the initial treatment of postmenopausal patients with 
metastatic breast cancer should consist of tamoxifen. Those patients who 
have mainly bone metastases and those who relapse on tamoxifen could 
benefit from aminoglutethimide. Premenopausal patients could be treated 
with bilateral oophorectomy with or without tamoxifen. However, those 
patients with ER negative tumors and/or younger age are best treated 
initially with cytotoxic chemotherapy. 
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PART THREE: CHEMOTHERAPY 
A large number of chemotherapeutic drugs are employed in the 
treatment of metastatic breast cancer. They fall in the following 
classes: alkylating agents (cyclophosphamide, melphalan); antibiotic 
antitumor agents (doxorubicin, mitomycin C); antimetabolites 
(methotrexate, 5-F1uorouraci 1); and vinca alkaloids (vincristine and 
vinblastine)*^ all of these agents have been tested as single agents with 
response rates ranging from 14% for vincristine to 22-2 7% for 
cyclophosphamide and 31-38% for adriamycin (doxorubicin)*^. 
COMBINATION CHEMOTHERAPY 
The first reports of the therapeutic efficacy of combination 
chemotherapy for metastatic breast cancer were by Greenspan*^ in 1963 and 
Cooper*^ in 1966. The latter was more widely accepted. The regimen 
consisted of: cyclophosphamide 2.5 mg/kg p.o. daily; methotrexate 25-50 
mg IV weekly; 5 Fluorouracil 12 mg/kg IV daily for 4 days, then 500 mg IV 
weekly; vincristine 35 ug/kg IV weekly; and prednisone 0.75 mg/kg p.o. 
daily, then taper (CMFVP). The length of this cycle was 8 weeks. Cooper 
reported "complete remissions" in 8 of 9 patients with lung metastases, 
19 of 22 patients with liver metastases, 14 of 16 patients with bone 
metastases, 7 of 8 patients with brain metastases, and 5 of 5 patients 
with massive skin involvement. "Complete remissions" lasted an average 
of 10 months. Many groups of i nvesti gators*^-73 have usecj modifications 
of this regimen with response rates of 53-68% (Table 2). Other reviewers 
report average response rates of 4 7% 66 and 50-60%66. 
Various clinical studies^* ^ examine the question of whether the 
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addition of vincristine is of vital importance in modifications of the 
Cooper regimen. Broader and associates^ compared a combination using 
CMFP plus or minus vincristine in 100 patients. Response rates were 
similar for both groups (CMFP - 28%, CMFVP - 30%). Ahmann et al.^6 
studied the combination CMP plus or minus vincristine and found lower 
response rate (46%), median duration of response (8.8 months) and 
survival (7.0 months) with the regimen containing vincristine (CMFVP) 
than with the combination without vincristine (CMP), (response rates- 
59%, median duration of response - 9.8 months, and survival - 9.0 
months). In general, there is no increase in response rates, response 
duration, or survival with vincristine containing modifications of "CMF" 
regimen than with the regimens without vincristine. In addition, the 
incidence of side effects particularly neurotoxicity and myelosuppression 
was higher with the vincristine containing combinations^,75# 
On the other hand, the addition of prednisone appears to be 
beneficial as shown by two studies (Table 2). Tormey and associates^* 
found higher response rates (63%), median duration of response (8.4 
months), and survival (16.4 months) with the CMFP regimen than with the 
CMF combination without prednisone (response rate - 57%, response 
duration - 4.5 months, and survival 14.5 months). A second group of 
investigators, Ramirez and coworkers^ had similar results in remission 
rates (CMFVP - 62.5%, CMFV - 44.2%) but found no significant difference 
in survival. They suggest that one possible explanation for the benefits 
of adding prednisone to CMF regimens could be that prednisone, by 
increasing the number of circulating leukocytes, allows larger doses of 
CMF to be tolerated613’ ^. 
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The question of modification in schedule has been examined by 
Hoogstraten and associates^. They studied a weekly (continuous) 
schedule using CMFVP versus the same combination using an intermittent 
schedule. Response rates were higher (59%) with the continuous regimen 
versus the intermittent schedule (40%). The median duration of response 
was similar for both groups (continuous regimen - 8.0 months, 
intermittent schedule - 10.0 months; difference not statistica 1 ly 
significant). Thus, they suggested that a continuous schedule is a more 
effective regiment in the treatment of metastatic breast cancer. 
Lastly, combination chemotherapy has been compared to single agents 
(Table 3)69,76-79. All of these studies show that combination regimens 
produce higher response rates with longer response duration and median 
survival than single agents. 
DOSE INTENSITY 
One issue which has recently gained increasing importance is the 
question of dose intensity. Hryniuk and Bush8(\ in a review article 
which addresses this question, stated that given the numerous 
manipulations of dose, schedules, and combinations, there should be a 
standardized method for comparing results obtained with the various 
chemotherapeutic regimens. They introduced the term dose intensity which 
they defined as mg/m^/wk. Taking Cooper's modification of his original 
schedule as the standard, the relative dose intensities of the various 
modifications of the Cooper regimen previously studied were calculated. 
They were able to show a positive relationship between the 
therapeutic outcome (response rate) and the average dose intensity. This 
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relationship is even more apparent when the actual amount of dose 
received after reductions made because of toxicities was employed. 
As one example, they analyzed results obtained by Hoogstraten and 
associates^ with a weekly (continuous) versus intermittent CMFVP 
combination regimen. Hryniuk and Bush‘d showed that the "low dose" 
weekly (continuous) combination, which was therapeutically superior to 
the intermittent combination, was actually the regimen with the higher 
dose intensity. 
Hryniuk and Bush^ also reviewed CAF containing combination 
regimens. Using the regimen employed by Bull and coworkers^, they 
demonstrated an even steeper linear relationship between dose intensity 
(dose actually delivered) and response rate than the one obtained with 
"CMP" regimens 
In a recent paper, Hryniuk^ states that dose intensity is not the 
only variable which affects response to treatment. In addition, the 
optimum duration of treatment needs to be taken into account since it has 
been said to determine the duration of remission. Overall, the dose 
intensity, upon which induction of remission depends, times the optimum 
duration of treatment determines the outcome of chemotherapy. 
ADRIAMYCIN 
Adriamycin (doxorubicin) has been shown to be the single most active 
agent in the treatment of advanced breast cancer. Reported response 
rates vary between 30-40%66 and 60%03. The dosage conventionally 
employed is 60 mg/m^ IV every three to six weeks^. 
Many investigators have studied the therapeutic effectiveness of 
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Adriamycin containing combination regimens. One review88 reports 
response rates of 60-80% in previously untreated patients. However, it 
appears that this higher response rate is not translated into increased 
survival. Our review of the literature found response rates varying from 
25-73% (Table 4)85-88. 
One of the major problems associated with the use of Adriamycin in 
advanced breast cancer is its toxicity. Not only does it cause nausea 
and vomiting, bone marrow suppression, alopecia and mucositis like many 
other cytotoxic agents, but its use is also associated with dose- 
dependent chronic cardiotoxicity82. Due to the latter, the cumulative 
dose limit should not exceed 450 mg/m2 84. 
The incidence of symptomatic congestive heart failure (CHF) has been 
estimated as 3-4% after a cumulative dose of 450 mg/m2 and 6-10% after a 
cumulative dose of 550 mg/m2. With doses exceeding 550 mg/m2, the 
incidence of CHF rises to 30%89,90. jn addition it has been shown that 
many patients experience cardiotoxicity at doses lower than the maximum 
cumulative dose of 450 mg/m2 9!>92. jn one Sj-ucjy by forti and 
associates9! 13% of the patients developed CHF. The median cumulative 
dose had been 405 mg/m2. 
With the advent of cardiac monitoring with noninvasive techniques 
and endomyocardial biopsy, it is possible to document subclinical cardiac 
injury at lower doses84’92. One study by Jain and associates92 examines 
the efficacy of epirubicin (4, epi Adriamycin) versus that of Adriamycin. 
Epirubicin is a doxorubicin (Adriamycin) analog which retains its 
therapeutic effects but has decreased potential for cardiotoxicity. It 
was shown that the response rate with epirubicin, using a dosage of 85 
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mg/rn^ IV every three weeks, was the same to that obtained with Adriamycin 
using the conventional dose of 60 mg/m^ IV every three weeks (i.e. 25%). 
Median duration of response was longer with epirubicin (11.9 months) than 
with Adriamycin (7.1 months). In addition, the median dose to 
development of cardiotoxicity was higher with epirubicin (935 mg/m^) than 
with Adriamycin (468 mg/m^). Ten patients developed CHF (epirubicin-4, 
Adriamycin-6). When the cumulative doses of these patients were looked 
at, it was found that those patients who received epirubicin developed 
CHF at a substantially higher dose (1134 mg/m^) than those who received 
Adriamycin (492 mg/m^). In addition, epirubicin was found to induce bone 
marrow suppression (on a molar basis) and GI toxicity less often than 
Adriamycin. It thus appears that epirubicin could be an alternative to 
Adriamycin alone or in combination for the treatment of patients with 
advanced breast cancer. 
"CMF" VERSUS ADRIAMYCIN 
Many clinical studies compare "CMF" combinations to Adriamycin as a 
single agent or Adriamycin containing combinations (Table 5)76,32,93-97. 
Most of these studies show that the response rates obtained with 
Adriamycin containing combinations was similar or higher than those 
obtained with modifications of the Cooper regimens. However, except for 
the study by Smalley et al.^^, comparing CAF versus CMFVP, this 
difference was not statistically significant. There was, however, one 
study by Hoogstraten and associates^ where the combination CMFP, given 
in a continuous schedule had statistically significantly longer response 
rate (59%) than Adriamycin as a single agent (39%). With respect to 
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median duration of response and survival, again, the Adriamycin 
containing combinations had similar or longer results than "CMF" 
combinations. This difference was only statistically significant in the 
study by Smalley et al.^. 
Two studies show "CMF" combinations with statistically longer median 
duration of response and/or median survival time. In the study by 
Hoogstraten et al.^, both CMFVP combinations had statistically 
significant longer median duration of response (10.3 months and 9.0 
months) and longer median survival times, though these were not 
statistically significant (15.3 months each), than Adriamycin alone 
(median duration of response - 4.0 months, median survival - 11.8 
months). Also, in the study by Carbone and associates^ the combination 
CMFP had a longer median duration of response (8.4 months) and 
statistically significant longer median survival (16.4 months) than 
Adriamycin as a single agent (median duration of response - 7.7 months, 
median survival - 13.7 months). 
It thus seems that the therapeutic efficacy of CMF(VP) regimens is 
probably similar to that of Adriamycin as a single agent and Adriamycin 
containing regimens. However, in view of the chronic dose-dependent 
cardiotoxicity, it seems wise to reserve Adriamycin for a second-line 
agent in those patients who have failed "CMF" combination treatment. 
SECOND-LINE TREATMENT 
Even though combination chemotherapy regimens can produce remission 
in over 50% of the patients*^, these responses are mostly partial and 
most patients end up with progression of their disease. Most patients 
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relapse within 10-13 months of starting treatment^*98. These patients 
can then be treated with other drug regimens: single agent or 
combinations. Unfortunately, second-line chemotherapy for the most part, 
has a lower response rate with shorter duration of response or time to 
disease progression and shorter survival. Oster^ comments on the fact 
that most patients with metastatic disease tend to die within one year of 
relapsing on their first-line chemotherapy. 
Various drugs have been evaluated in the treatment of patients with 
metastatic disease who have relapsed on their first chemotherapeutic 
and/or hormonal treatment. Adriamycin has turned out to be the most 
effective single agent with response rates ranging between 23-38% (Table 
5)92,100-102# These numbers are substantially lower than the response 
rate obtained with previously untreated patients (over 50%)^. Duration 
of response ranges from 3-12 months. 
Mitomycin C has also been studied by multiple groups of 
investigators as an alternative to Adriamycin in second-line treatment of 
metastatic breast cancer (Table 7)103-106^ Unfortunately, response rates 
are much lower (18-26%). In addition, one group^ obtained no responses 
in 43 patients evaluated. 
The next step in second-line chemotherapy has been the evaluation of 
combinations containing Adriamycin, mitomycin C, and vinca alkaloids 
(vinbl asti ne-Vb , vincristine-Vc, and vindensine-Vb) (Table 8)107-113^ 
Response rates with two drug combinations range from 7-40%^7-liO^ Other 
studies include the alkylating agent di bromoducitol ^ ^ and the 
investigational drug ICRF-113 in combination with Adriamycin and 
mitomycin C or vincristine. Response rates obtained were 27-43% for the 
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combination AM plus di bromoducitol H1-H2 anci 16% for AV plus 
dibromoducitol and ICRF-159113> 
In view of the fact that combinations containing Adriamycin and 
mitomycin C or vinca alkaloids have response rates around the 30% range, 
various groups of investigators have studied combinations of these three 
agents (Table 9)99*114-116 response rates range from 31-73%. 
This study was designed as a randomized clinical trial to compare 
the current standard for second-line chemotherapy in metastatic breast 
cancer - Adriamycin with a combination using a low dose of Adriamycin 
with vinblastine and mitomycin C. 
CLOSING REMARKS 
It should be kept in mind, that breast cancer, particularly after 
the first or second relapse, is not a curable disease^ and thus, 
palliation and prolonged survival become the goal of therapy. In 
conclusion, the current recommended initial treatment for metastatic 
breast cancer is endocrine therapy. For those patients who fail such 
treatment or who have recurrence of their disease, chemotherapy is the 
next step. The one exception appears to be those patients with rapidly 
progressive disease and/or extensive visceral metastases who seem to do 
better with chemotherapy as their initial treatment^. For the rest, 
endocrine therapy is said to be associated with better quality of life 
and longer survival28,44o 
With respect to chemotherapeutic regimens, combination chemotherapy 
with "CMF" type regimens appears to be the therapy of choice over single 
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agents, the best of which is Adriamycin. However, although combination 
therapy is associated with increased response rate and prolonged 
survival, the increased toxicity associated with a larger number of drugs 
is an important consideration particularly in the elderly and very sick 
patients. It is important to know that these regimens do not appear to 
be cross-resistant; and therefore, failing to respond to or progressing 
on one does not preclude response to the other. 
Since a large number of patients do have progression of their 
disease on first-line chemotherapy, second-line chemotherapy has become a 
very important area of investigation. Single agent chemotherapy with 
Adriamycin is the current recommended treatment with response rates of 
23-38%92,10U-1U2. Recent studies^^*^^ show that combination 
chemotherapy with Adriamycin, vinblastine and mitomycin C also appears to 




PART FOUR: THE STUDY 
METHODS 
All women seen in the Yale-New Haven Hospital and affiliated clinics 
during the period of March, 1981 to September, 1985 who had 
histologically confirmed adenocarcinoma of the breast with measurable 
recurrent or distant metastatic disease and had failed prior treatment 
with CMF or its combinations were eligible for the study. All patients 
had previously received chemotherapy either as adjuvant or as treatment 
for metastatic disease with or without hormone therapy and had relapsed. 
Estrogen receptor levels were obtained, when available, both for the 
primary tumor and recurrence. Those patients with a positive ER status 
had to have been unsuccessfully treated with hormonal therapy prior to 
entering this study. 
Criteria for exclusion included: (1) having received prior 
treatment with Adriamycin, mitomycin C and/or vinblastine; (2) being more 
than 75 years of age; (3) having evidence of cardiac disease (measured by 
a ventricular ejection fraction of <50%); and/or (4) having an expected 
survival time of less than 30 days. 
In order to begin treatment, patients had to not have received any 
therapy in the last 4 weeks and had to have given appropriate informed 
consent. 
Pretreatment evaluation included a complete history and physical 
exam with measurement of all lesions and assessment of all disease sites. 
Baseline studies included: complete blood count (CBC), platelet count, 
calcium, blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen 
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(CEA), and liver function tests (bilirubin - tota 1/indi rect), serum 
glutamic-oxalocetic transaminase (SGOT), and alkaline phosphatase; chest 
x-ray, bone and liver scans, and left ventricular ejection fraction. 
Performance status of the patients at initiation of therapy was 
assessed according to the guidelines of the ECOG performance scale: 
0. ambulatory, assymptomatic and able to carry out their normal daily 
activities; 1. ambulatory, but experiencing symptoms from disease and 
restricted in their daily activities; 2. bedridden <50% of the time; 
3. bedridden >50% of the time; and 4. bedridden all the time. 
Follow-up studies were performed on all the patients in order to 
monitor the extent of disease progression and response to therapy. A 
history and physical exam was done every 4 weeks. Blood counts (CBC and 
platelet) were obtained every 4 weeks. Other blood studies, including 
BUN, creatinine, calcium, and liver function tests (same as above) were 
performed every 6 weeks. Chest x-rays were obtained every 3 months if 
the patient's previous studies were normal, or every 8 weeks if such 
studies indicated metastatic disease. Ventricular ejection fraction 
tests, to monitor Adriamycin's potential cardiac toxicity, were repeated 
after the patient had received a cumulative dose of 300 mg/m^. 
Patients were randomized into 2 treatment groups: Adriamycin as a 
single agent (Adriamycin), or Adriamycin in combination with vinblastine 
and mitomycin C (AVM) • The Adriamycin group received 60 mg/m^ of 
Adriamycin IV on day 1 every 3 weeks. The AVM group received 30 mg/m^ of 
Adriamycin IV on day 1 every 4 weeks, 6 mg/m^ of vinblastine IV on day 1 
every 4 weeks, and 10 mg/m^ of mitomycin C IV on day 1 every 8 weeks. 
Drug dosages of AVM and Adriamycin were started at 50% if the 
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patients had experienced cytopenias prior to entering the study (measured 
by a hematocrit >30%, a white blood count (WBC) <2000/ul, and/or a 
platelet count <100,000/ul. If on day 1 of the treatment cycle the WBC 
was >3500/ul and the platelet count was >100,000/ul the dose was 
increased by 25%. 
If bone marrow depression occured during treatment, drug dosages 
were reduced by 50% if the patient had a WBC of 2500-3499/u 1 and a 
platelet count of 75,000-99,000/u 1. Treatment was held if the patient 
had a WBC <2500/ul and a platelet count <75,000/ul. 
Adriamycin dose was held if the patient had a ventricular ejection 
fraction <45%. At this point the patient was taken out of the study due 
to cardiotoxicity and other treatment options were explored. Adriamycin 
dose was reduced by 50% if the patient had a total bilirubin of 1.5-3.0 
mg% or by 75% if the patient had a total bilirubin >3.0 mg%. 
Complete response was defined as a disappearance of all known and 
measurable disease, as confirmed with x-rays, bone and liver scans. The 
response should last at least 4 weeks. 
Partial response was defined as regression of 50% or more of the sum 
of the cross-perpendicular dimensions of the largest diameter of all 
measurable lesions. The response should last at least 4 weeks. 
Stabilization was defined as a reduction of <50% or a progression of 
<25% of the original measured lesions (size parameters measured as 
above). No new lesions could have appeared in this time period. 
For evaluation purposes, patients who were documented as having 
stable disease were classified as non-responders together with those who 
had disease progression. 
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Those patients who were documented as having achieved a response to 
treatment or disease stabilization continued to receive treatment until 
there was evidence of disease progression. When a patient was determined 
to have relapsed, treatment according to this protocol was terminated and 
other treatment alternatives were explored. At this point all blood 
studies, chest x-rays, bone and liver scans were repeated. 
Response was evaluated in terms of survival and time to disease 
progression. 
Survival was measured from the date of initiation of therapy, in 
this study, to the date last seen or date of death. The time to disease 
progression was defined as the time from initiation of treatment to the 
time when the patient had a documented disease progression. 
The difference between the two treatment arms was analyzed using the 
Chi Square test. 
Survival and time to progression data were calculated according to 
the actuarial method of Kaplan and Meier ^ and the significance of 
differences was analyzed using the Mantel-Cox statistical test. 
Difference in survival times and time to progression between responders 
and non-responders was analyzed. Data were also evaluated for 
differences in the following parameters: number of disease sites at 
initiation of treatment, performance status, disease-free interval, stage 
at diagnosis, and menopausal status at initiation of the study. Data for 
estrogen receptor status were not included in the analysis because the 
number of patients with information available was too small. 
The cost of each drug regimen was calculated based on the cost at 
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Yale-New Haven Hospital as of July, 1987 (latest figures available at the 
time of writing this manuscript) (Table 10). 
PATIENTS AND RESULTS 
Fifty-eight patients were entered in the study. Four patients were 
considered unevaluable; three had been randomized into the Adriamycin 
treatment group and one to the AVM treatment group. One of the 
Adriamycin patients died after randomization without receiving any 
treatment. Another patient received ten courses of treatment at 100% 
dose, but also received taxomifen during eight of the ten treatments. 
The third patient died of a respiratory arrest four days following her 
first treatment at 100% dose. On autopsy, she was documented to have had 
lymphangitic disease of the lung and metastases in the liver, mediastinal 
and para-aortic lymph nodes, adrenal glands, pancreas, bone and opposite 
breast. The patient who was randomized into the AVM treatment group 
refused any further therapy after the first treatment. She was admitted 
to the hospital the following day and expired two weeks later. However, 
this patient had been admitted to the hospital one week prior to the 
first treatment because of increased shortness of breath, generalized 
weakness and progression of her disease. Of the remaining 54 evaluable 
patients, 26 were in the Adriamycin treatment group and 28 were in the 
AVM treatment group. 
Patient Character!'sties 
Patients characteristics are presented in Table II, subdivided by 
treatment group. 
The age median (Adriamycin-52; AVM-54) and range (Adriamycin 35-74; 
AVM 29-73 ) was similar for both groups. Most patients were 
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postmenopausal at the time of study [23 (89%) Adriamycin patients; 21 
(75%) AVM patients]. 
With respect to staging of the primary tumor, most patients (54%) 
fell in the 111-1V category [Adriamycin-16 (62%); AVM-14 (50%)]. The 
difference may be accounted for by the fact that 5 of the AVM patients 
versus only 3 of the Adriamycin patients had an unknown status. 
Contrary to expected for this group of patients' performance status, 
a higher percentage were ambulatory with a performance status of 0 or 1 
[Adriamycin-20 (77%); AVM-20 (71%)]. Three patients in the Adriamycin 
group had an unknown status. Within this category there is a difference 
between treatment arms: 5 of the 20 Adriamycin patients (25%) were 
asymptomatic versus 11 of the 20 AVM patients (55%). Eleven patients 
were non-ambulatory with a performance status of 2 or 3. No patient had 
a performance status of 4. Almost all the patients were bedridden <50% 
of the time with a performance status of 2 [Adri amycin-6 (100%); AVM-4 
(80%)]. Only one patient was bedridden >50% of the time with a 
performance status of 3. 
The disease-free interval (DFI) was defined as the time from initial 
diagnosis to the time of first recurrence. This interval was 
approximately the same for both treatment groups (Adriamycin-25.6 months, 
range 0-72 months; AVM-22.0 months, range 0-72 months). Seven patients 
(Adriamyci n-3; AVM-4) presented with metastatic disease and were 
considered to have a 0FI of 0. 
Previous Treatment 
Previous treatment received by the patients before entering the 
study is shown in Table 12. Most patients had had surgery as their 
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primary treatment (Adriamycin-24; AVM-23). Of these 2 Adriamycin 
patients and 4 AVM patients had had lumpectomies, and the rest had had 
either a simple or modified radical mastectomy. One patient, in the AVM 
group, had had a radical mastectomy. Three of the remaining five 
patients who had not had surgery received primary radiation therapy. 
All the patients in this study have been treated with CMF 
chemotherapy, either adjuvanct [Adriamycin-12 (46%); AVM-13 (46%)] or 
after recurrence [Adriamycin-15 (58%); AVM-14 (50%)]. Two patients in 
the Adriamycin group received CMF chemotherapy both adjuvanct and after 
recurrence and failed both treatments. 
One patients in the Adriamycin group had been treated with hormone 
therapy as primary treatment. Twelve patients [Adriamycin-6 (23%); AVM-6 
(21%)] had received hormone therapy adjuvanct. Approximately two-thirds 
of the patients [Adriamycin-18 (69%); AVM-17 (61%)] had been treated with 
hormone therapy after recurrence either alone or in combination with CMF 
chemotherapy. 
Three patients in the Adriamycin treatment group and two patients in 
the AVM treatment group had had an oophorectomy, either surgical or 
radiation, following their first recurrence. 
Sites of Metastatic Disease at Initiation of Therapy 
Sites of metastatic disease at initiation of therapy subdivided by 
treatment arm, showing both number and percentage of patients with 
metastatic disease and breakdown by site are presented in Tables 13 and 
14. 
The majority of the patients [Adriamycin-21 (81%); AVM-21 (75%)] 
presented with metastatic disease at 2 or more sites. Within this group, 
only 3 (12%) of the Adriamycin patients and 4 (14%) of the AVM patients 
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had widely disseminated disease with involvement of more than 3 sites. 
The single most common site of metastatic disease at initiation of 
study was bone [Adriamycin-19 (31%); AVM-20 (28%)]. Approximately half 
of the patients [Adriamycin-14 (56%); AVM-13 (46%)] had visceral disease 
at one site with involvement of the lung or liver. One patient in the 
Adriamycin group had both liver and CNS involvement. Three patients in 
the AVM group had involvement of both the liver and the lungs. One of 
these patients had involvement of the kidney. 
On-Study Time 
On-study time was defined as the time elapsed between the date of 
first treatment to the date last seen or the date of death. The 54 
evaluable patients had a mean on-study time of 234 days, range (27-784 
days). The 28 AVM patients had a longer on-study time (mean-268 days, 
range 34-784 days) than the 26 Adriamycin patients (mean-268 days, range 
34-784 days) than the 26 Adriamycin patients (mean-198 days, range 27-563 
days). 
The 54 evaluable patients received a total of 300 treatment courses. 
The 26 Adriamycin patients received a total of 117 treatment courses with 
a mean/patient of 4.5 cycles of treatment whereas the 26 AVM patients 
received a total of 183 treatment courses with a mean/patient of 6.5 
cycles of treatment. 
Response to Therapy 
Response to therapy, subdivided by treatment arm is shown in Table 
15. 
Twelve (22%) of the 54 evaluable patients had an objective partial 
response: 4 (15%) of the Adriamycin patients and 8 (29%) of the AVM 
patients. No patient had a complete response. This difference was not 
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statistically significant (p>0.2). 
Within the non-responders, three-quarters (33 patients) had 
progressive disease: 16 (73%) of the 22 Adriamycin patients and 17 (85%) 
of the 20 AVM patients. The remaining 9 non-responders had stable 
disease. 
Survival 
Survival time for all patients was analyzed and is presented in 
Table 16 and Figures 1-8. 
Median survival time for all patients was 8.41 months. When 
separated into treatment groups, the Adriamycin patients had a median 
survival time of 7.56 months and the AVM patients had a median survival 
time of 9.00 months. This difference was not statistically significant 
(p=.35). 
Patients who were classified as responders had a statistically 
significant (p =.01) longer median survival time (20.40 months) than the 
patients who did not respond (7.33 months). 
Separating the patients by numbers of sites of disease at the time 
they entered the study showed no statistically significant difference in 
median survival times (p=.19) between the patients who had 1 site of 
disease (9.66 months), 2 or 3 sites of disease (7.59 months) or >3 sites 
of disease (5.82 months). 
The mean survival time of the patients who were ambulatory (9.66 
months) was found not to be significantly higher (p=.06) than that of the 
patients who were non ambulatory (6.87 months). 
In order to analyze data for disease-free intervals, all patients 
were divided into three groups depending on the length of time they had 
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been disease-free prior to their first recurrence: (0-6, 7-18 or >18 
months). Statistical tests demonstrated no significant difference 
(p=.89) between the median survival times (9.66 months, 8.41 months, and 
8.71 months respectively) of the patients in these groups. 
Survival data was also analyzed with respect to stage of tumor at 
initial diagnosis. It was found that patients with Stage III tumors had 
overall shorter (6.38 months) median survival (9.79 months, 9.33 months, 
and 9.66 months, respectively) than those with Stage I and II tumors. It 
is not clear why patients with Stage IV tumors had a longer median 
survival than those with Stage III tumors. One possibility is that these 
patients, because they presented with metastatic disease at diagnosis, 
had not been as heavily pre-treated when they entered this study. 
There was no statistically significant difference (p=.12) between 
the median survival time of the premenopausal (12.85 months), and the 
postmenopausal (7.56 months) patients. 
Time to disease progression 
Another parameter used to analyze the data in this study was time to 
disease progression. Data is presented in Table 17 and Figures 9-16. 
The median time to disease progression for all patients was 4.50 
months. When separated by treatment groups, the AVM patients had a 
longer (p=.03) time to disease progression (5.91 months) than the 
Adriamycin patients (3.84 months). 
Looking at all patients, responders had a significantly longer 
(p=0.03) time to disease progression (10.12 months) than non-responders 
(3.22 months). 
Dividing the patients into three groups depending on the number of 
disease sites at the time they entered the study, showed no statistical 
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significant difference (p=.70) between those who had 1 site of disease 
(median time to progression - 3.22 months), 2-3 sites of disease (median 
time to progression - 5.59 months) or >3 sites (median time to 
progression - 3.83). 
There was no statistically significant difference (p =.91) in the 
time to disease progression in the patients who were ambulatory (3.84 
months) and those were non-ambulatory (5.91 months). 
In terms of disease free interval there was no statistically 
significant difference (p=.42) in the time to disease progression of the 
patients in the three groups (disease free intervals 0-6, 7-18, and >18 
months; time to disease progression 3.02, 3.84, and 5.59 months 
respectively. 
Time to disease progression was analyzed with respect to stage of 
tumor at diagnosis. Overall, patients with Stage I and II tumors had a 
longer time to disease progression than those with Stage III and IV 
tumors. 
There was no statistically significant difference (p=.99) in the 
time to disease progression between the patients who were premenopausal 
(5.59 months) and those who were postmenopausal (4.50 months) at the time 
they entered the study. 
For 22 patients the study was ended for reasons other than disease 
progression (Adriamycin-12, AVM-10). Of these, seven patients 
(Adriamycin-3, AVM-4) died while receiving treatment without having had 
documented disease progression. The remaining 15 patients (Adriamycin-9, 
AVM-6) were taken out of the study for various reasons. This date was 
used as their date of disease progression. 
Of the nine Adriamycin patients, five were changed either to weekly 
Adriamycin or to AVM after a total dose of 300 mg/m2. None of them had 
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experienced cardiac toxicity. One patient was hospitalized for a small 
bowel obstruction and was treated with the wrong protocol after 
discharge. Another patient was changed to AVM for no apparent reason. 
The remaining two patients were lost to follow-up. 
Two of the six patients receiving AVM stopped treatment due to 
shortness of breath. It should be noted that both had a normal 
ventricular ejection fraction. The other 4 patients were still receiving 
treatment at the time this study was ended. 
Sites of Metastatic Disease at Progression 
Sites of metastatic disease at progression, subdivided by treatment 
arm showing both number and percentages of patients with metastatic 
disease and breakdown by site, are presented in Tables 18 and 19. 
Most patients had progression of their disease in 3 or fewer sites 
[Adriamycin-21 (84%), AVM-21 (84%)]. Of the Adriamycin patients, 
approximately half [11 (52%)] had disease in 0 or 1 site, and half [10 
(48%)] had disease in 2 or 3 sites. Only 4 patients in each group had 
disease in 4 or more sites. Overall, the majority of the patients had 
recurrence at the same sites of metastatic disease prior to initiation of 
therapy. 
The most common site involved at disease progression was bone 
[Adriamycin-13 patients (52%), AVM-16 patients (64%)]. Visceral disease 
with involvement of lung, liver or CNS was documented in 16 (64%) 
Adriamycin, and 14 (56%) AVM patients. One of the Adriamycin patients 
and 2 of the AVM patients had involvement at 2 of these sites. 
Toxicities 
The most significant toxicities experienced by the patients in this 
study are presented in Table 20. 
The lowest white blood counts seen in the interval between cycles of 
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21 (57%) patients, AVM-17 patients of 23 (74%) patients]. Such blood 
counts were seen in 17 of 53 (32%) evaluable courses in the Adriamycin 
treatment group and in 30 of 89 (34%) evaluable courses in the AVM 
treatment group. Only 6 (14%) patients had white blood cell counts >1000 
cells/ul^. Five of these were in the Adriamycin treatment group. 
Platelet counts of <100,000 cells/ul were seen in 13 of 44 (24%) 
patients [Adriamycin-5 of 21 (24%) patients, AVM-8 of 23 (34%) patients]. 
Such platelet counts were seen in 5 of 52 (10%) evaluable courses in the 
Adriamycin patients and 12 of 89 (14%) evaluable courses in the AVM 
treatment group. No platelet counts <20,000 cells/ul were seen. 
The percent of optimal dose administered per cycle was averaged for 
each treatment arm. Results are presented on Figure 17-19. It should be 
noticed that a higher percentage of the ideal dose was able to be 
administered with the AVM combination than with Adriamycin with the AVM 
combination than with Adriamycin as a single agent. 
Figures 20 and 21 show the relationship of the platelet count 
(mean/cycle) and percent of ideal dose (mean/cycle) administered for each 
treatment group. It may be observed that, for the most part, there was 
not much variation in terms of the platelet count as the percent of ideal 
dose was decreased for both groups of patients (Adriamycin: 231,000- 
378,000 cells/ul, AVM: 180,000-291,000 cells/ul). 
The mean (range) WBC counts per cycle were plotted by course of 
treatment for each of the treatment groups on Figure 21. Looking at the 
mean WBC count per cycle again, there is not much variation throughout 
the different cycles of treatment for both treatment arms. However, in 
general, the mean WBC count in the AVM treatment group tends to be 
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slightly higher than in the Adriamycin treatment group. 
None of the patients experienced symptoms of cardiac toxicity. Two 
patients, however, were changed to a different regimen because their 
ejection fraction had significantly declined from 69-60% and 74-50%, 
respectively, after a cumulative Adriamycin dose of 300 mg/m^. However, 
10 patients (Adriamycin-4, AVM-6) received >300 mg/m^, and 11 patients 
(Adr i amycin-7 , AVM-4) received between 200-300 mg/m^ of Adriamycin 
without developing cardiac toxicity. 
Two patients deserve special mention. One patient declined further 
therapy following her complaint of shortness of breath, secondary to 
Adriamycin, after a total dose of 161 mg/m^. Her ventricular ejection 
fraction, however, was 80%. One patient in the AVM group developed 
bigeminy after a total dose of 300 mg/m^. Her ventricular ejection 
fraction, however, was 62%. Her Adriamycin was held, she was taken out 
of the study at this point, and her cardiac problem was controlled with a 
hi gh dose of Inderal . 
None of the patients developed neurotoxicity from vinblastine. 
One patient was hospitalized due to severe liver disease and 
declined further treatment; however, this patient had metastatic disease 
in her liver at the time she entered the study. 
Seven patients developed sufficiently profound thrombocytopenia to 
require hospitalization (Adriamycin-4, AVM-3). One of these patients 
also had a fever. Another patient was admitted with GI bleeding. 
Some patients experienced nausea and vomiting, stomatitis, tissue 
irritation, rashes, and alopecia during treatment, but all of these were 
considered minor toxicities. 
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Seven patients died during treatment. Five of the deaths were 
primarily due to progressive disease (Adriamycin -3, AVM -2); the other 
two (AVM) were of unknown etiology. 
Eleven patients were still alive at the date last seen; 6 in the 
Adriamycin group, and 5 in the AVM group. None of these patients were 
disease-free. Four patients had no evidence of disease progression at 
the date last seen, and were still receiving treatment at the time the 
study was ended. All of them were in the AVM treatment group, and had 
experienced a partial response. Three patients, all from the Adriamycin 
group, had been taken out of the study after a total Adriamycin dose of 
300 mg/m^. However, none of them had developed signs of cardiac 
toxicity. Two of the Adriamycin patients were lost to follow-up. The 
remaining 2 patients have had documented disease progression and were 
receiving other treatment. 
Cost 
Data used to calculate costs was presented in Table 10. Total 
figures for each treatment group were adjusted for a four week period. 
It was found that the cost per month of treatment was suprisingly more 
expensive for the single drug ($307.29), than for the three drug 
combination ($263.91). 
DISCUSSION 
The high rate of recurrence and short duration of response obtained 
with first-line chemotherapy for advanced breast cancer (usually "CMF" 
regimens) is well-known. Adriamycin is the current standard of treatment 
for patients with metastatic breast cancer refractory to conventional 
chemotherapy. However, as already discussed, this drug is associated 
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with dose-dependent cumulative cardiotoxicity which has limited its use 
to 450 mg/m^. Usually treatment need to be changed once this dose has 
been exceeded. Unfortunately, the number of single agents and 
combinations shown to be effective for third-line treatment is small and 
the response is quite poor HO. This study compares one such combination 
(Adriamycin, vinblastine, and Mitomycin C) to single agent Adriamycin. 
One of the approaches to improve palliation of disease and prolong 
survival is to employ combination regimens containing Adriamycin as 
second-line treatment. The idea is that, by giving Adriamycin with two 
other synergistic, but potentially less toxic drugs, one could achieve 
equal or greater responses with a lower dose of Adriamycin. Thus, it 
would permit less drug to be given over a longer period of time. This 
has been one of the approaches suggested by Jain et al .^2 for reducing 
cardiac toxicity. 
Before analyzing the results, it should be noted that the patients 
in this study are of a poor prognostic category with respect to the 
course of metastatic disease. Their disease-free interval was generally 
less than two years. According to Cutler and associates H this gives 
them a median survival after relapse of 15 months. In addition, most 
patients had between two and three sites of metastatic disease at 
relapse. This places them in category C (mixed sites of metastatic 
disease) according to Fei and coworkers and therefore, their expected 
survival after relapse should be approximately 17 months, or 9 to 12 
months according to Cutler and associates n0 information was 
available with respect to response to first-line treatment. 
Also of note, this group of patients had been heavily pre-treated 
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with first-line agents. Approximately, one half of the patients had been 
treated with chemotherapy, the other half had received hormone therapy. 
Ten percent of the patients had been treated with combination 
chemotherapy and endocrine therapy at relapse. 
Response rates were higher with the AVM combination regimen (29%) 
than with Adriamycin as a single agent (15%). All of these responses 
were partial remissions. This difference, however, was not statistically 
significant (p>.2). Most likely this was due to the small number of 
patients who responded in both treatment groups (Adriamycin-4, AVM-8). 
With respect to response duration, the patients treated with the AVM 
combination had a longer time to disease progression (5.91 months) as 
compared to the patients treated with Adriamycin alone (3.84 months). 
This difference was statistically significant (p<.05). As expected, 
responders had a significantly longer time to progression than non¬ 
responders (i.e., 10.12 versus 3.22, p=.003). However, none of the 
parameters evaluated: namely, numbers of sites of metastatic disease at 
initiation of study, performance status, disease-free interval, and 
menopausal status was of prognostic value in evaluating time to 
progressi on of disease. The only factor that appears to make a 
difference is stage at diagnosis. Overall, the patients with more 
advanced disease at diagnosis (Stages III and IV) had a significantly 
shorter time to progression than those with less advanced disease (Stages 
I and II). 
In terms of survival, the patients in the AVM treatment arm had a 
longer, though not statistically significant, median survival (7.56 
months) than those in the Adriamycin treatment group (9.00 months). As 

50 
expected, responders had a significantly longer median survival time 
(20.40 months) than non-responders (7.33 months). None of the other 
parameters, already mentioned, were found to be of prognostic value 
except for stage at diagnosis. Again, those patients with more advanced 
disease at diagnosis (Stages III and IV) had a significantly shorter 
median survival than those with less advanced disease (Stages I and II). 
Overall, results obtained with the AVM combination were similar to 
those reported in previous studies 99,114-116. 
Luikart and coworkers using a combination of Adriamycin 30 
mg/m^ on day one every eight weeks (the same regimen employed in this 
study) in previously treated patients, obtained a 33% (nine responders) 
response rate. Of these nine responders, three were complete responses, 
and six were partial responses. Median survival for this group of 
patients was 264 days (approximately 8.7 months) which is comparable to 
our group of patients in the AVM treatment arm (9.00 months). Time to 
progression was 116 days (approximately 3.8 months) which is shorter than 
that observed in this study for the AVM patients (5.91 months). Luikart 
et al.H6, observed that, in general, patients with one or two sites of 
metastatic disease tended to have more responses or stabilization of 
disease than those with three or more sites. This was not true in this 
study. Of the twelve patients who responded, four in the AVM group, and 
three in the Adriamycin group had metastatic disease at three or more 
sites prior to initiating treatment. 
Another study by Borowik and colleagues using these same agents 
in different doses (Adriamycin 45 mg/m^ and vinblastine 4.5 mg/m^ IV 
every three weeks and mitomycin C 10 mg/m^ IV every six weeks) in 
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previously treated patients reported a response rate of 24.3% with a 
median duration of 5+ months. Their response rate was much higher (38%) 
in patients who received over 80% of the calculated dose. They found 
that those patients who received the combination regimen after failing 
adjuvant CMF had a higher response rate (45%) compared to those who had 
failed CMF for advanced disease (20%). In addition, they showed that 
response rate to the combination regimen was related to disease-free 
interval. Those patients with a DFI greater than 24 months had a higher 
response rate (41%) than those with a DFI less than 24 months (10%). 
Two other studies 99,115 evaluated a combination containing 
Adriamycin, mitomycin C, and vincristine instead of vinblastine. Shipp 
and associates reported a 31% response rate with a median duration of 
5 months with a combination of Adriamycin 40 mg/m^ and vincristine 1.5 
mg/m^ on day one and 22 and mitomycin C 10 mg/m^ on day one every six 
weeks in previously treated patients. Of the 11 responders, one had a 
complete response, the remaining 10 had partial responses. Median 
survival for this group of patients was 7.9 months. Like Borovik et 
al.114, they too found that response rate was significantly higher (53%) 
for those patients who were treated with the combination regimen after 
adjuvant CMF, compared to those who had failed CMF for advanced disease 
(14%). However, no other pretreatment characteriStic evaluated: age, 
performance status, number of and dominant sites of metastatic disease, 
disease-free interval, and estrogen receptor concentration, was found to 
be of prognostic value in predicting response. 
The other group of investigators Osier and coworkers ^9 obtained a 
much higher (73%) response rate with a longer median duration (8.0 
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months) and survival (18 months). Of their 11 patients who responded, 
three had complete remissions. One possible explanation for this high 
response rate could be that this was a small sample of patients 
approximately one-half of which had soft tissue disease. Eight of these 
responses were in soft tissue. The other four were in visceral sites 
(lung or liver). None of the patients had metastatic disease in bone. 
Results obtained with Adriamycin as a single agent in this study 
(response rate - 15%, time to progression - 3.84 months, and survival 
7.56 months) were somewhat lower than those reported by other researchers 
(23-38%) 89-91# Jain ancj associates 92} Gotlieb and coworkers and 
Fredericksen and colleagues employed dosages of Adriamycin 60 mg/m^ 
IV 60-75 mg/m^ IV, and 70 mg/m^ IV every three weeks, similar to those 
used in our study (60 mg/m^ IV every 3 weeks). They reported response 
rates of 25%, 30%, and 23%, respectively. Median duration of response 
ranged from 3+ to 11.9 months. Creech and coworkers 96^ using a lower 
dose of Adriamycin 20 mg/m^ on day one and eight every 23rd day, obtained 
a 27% response rate with a median duration of 7 months. 
There are a couple of possible reasons which could explain the lower 
response rate obtained in this study. First, this was a group of heavily 
pretreated patients with poor prognostic disease, for many of whom 
Adriamycin was a third-line, rather than a second-line, agent. Second, 
and probably because of the above mentioned reasons, they only tolerated, 
on the average, 75% of the optimal dose of Adriamycin which they were to 
receive. 
Hematologic toxicity was moderate for both treatment groups. 
Leukopenia (WBC count <2000/ul) and thrombocytopenia (platelet count 
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<100,000/ul) were similar for both treatment groups when analyzed in 
terms of evaluable courses. Variation in both WBC count and platelet 
count with respect to percent of optimal dose administered is small and 
similar for both treatment arms. However, overall, a higher percentage 
of the optimal dose was able to be administered with the AVM combination 
than with Adriamycin as a single agent. This could have been due to the 
fact that the combination was given every four weeks, whereas the single 
drug was given every three weeks. 
Cardiac toxicity was not observed in this study. Two patients, both 
in the Adriamycin treatment group, had to be changed to a different 
regimen due to a fall in ejection fraction, but for neither patient had 
there been a significant change (74% to 50% and 69% to 60%). 
Furthermore, neurotoxicity due to vinblastine was also not seen in any of 
the patients. 
Finally, the question of cost needs to be addressed. It would seem 
logical that a single drug would be cheaper and, therefore, preferred 
over a three drug combination. However, because this combination 
contains only one-half of the standard Adriamycin dose, and is given 
every four, instead of every three, weeks, it turns out that the AVM 
regimen is actually less expensive ($263.91/month) than Adriamycin as a 
single agent ($307.29/month). 
In summary, the combination of Adriamycin, vinblastine and mitomycin 
C appears to be at least as effective as Adriamycin as a single agent. 
The AVM combination had a significantly longer time to disease 
progression, and allowed for a higher percentage of the optimal dose to 
be administered. It also had a higher response rate and median survival. 
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but these differences were not statistically significant most likely due 
to the small number of patients involved. Furthermore, the combination 
was less expensive, on a monthly basis, than single agent Adriamycin. 
Since toxicity was similar for both regimens, it appears worthwhile to 
employ this combination as second-line treatment for patients with 
metastatic breast cancer. 
It has been previously established that epirubicin is as 
therapeutically efficacious as Adriamycin, but with less potential for 
cardiac toxicity, thus allowing for a higher cumulative dose to be 
administered 92. jn the future, it would be important to determine the 
efficacy of a combination of epirubicin with vinblastine and mitomycin C 
as second-line chemotherapy in patients with advanced breast cancer. 
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TABLE 1: CORRECTED 10 YEAR SURVIVAL 
(PERCENTAGE) BY STAGE AND GRADE* 
Stage Grade I Grade II Grade III 
I 73 65 62 
II 59 27 17 
III 53 23 12 
IV 11 3 4 
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TABLE 10: COST OF EACH DRUG REGIMEN 
ADRIAMYCIN AVM 
Drug(s): Adriamycin 
50 mg vial $144.44 $144.44 
10 mg vial $ 31.39 $ 31.39 
Vinblastine 
10 mg vi al $ 22.89 
Mitomycin C 
20 mg vi al $208.88 
4 mg vial $ 61.85 
Administration Charges: 
Cost per drug $ 10.00 $ 20.00/$30.00* 
Infusion charge $ 60.00** $ 60.00** 
* Amount was calculated as $30.00 in cycles when all three drugs were 
given (every eight weeks) and as $20.00 in cycles when only two drugs 
were given (every four weeks). 
** Cost per cycle (same for both regimens) 

TABLE 11: GENERAL CHARACTERISTICS OF PATIENTS WITH 





Number of Patients 28 29 
Number of Evaluable Patients 26 28 
Median Age in Years (Range) 52 ( 35-' 74) 54 (29-• 73) 
Stage at Diagnosis 
I 3 1 
II 4 8 
III 10 5 
IV 6 9 
Unknown 3 5 
Menopausal Status at Study 
Premanopausal 3 (12%) 7 (25%) 
Postmenopausal 23 (89%) 21 (75%) 
Performance Status 
Ambulatory 0 5 11 
20 20 
1 15 9 
Non-ambulatory 2 6 4 
6 5 
3 0 1 
Unknown 0 3 
Median Disease-Free Interval in Months (Range) 25 .6 (0*- 72) 22 (0*-72 
* Patients presented with metastatic disease 
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TABLE 12: PRIOR TREATMENT OF PATIENTS WITH 
ADVANCED BREAST CANCER BY TREATMENT ARM 




Mastectomy 22 19 
Lumpectomy 2 4 
Radiation Therapy 
Pri ma ry 1 5 
Adjuvant 4 1 
For Relapse 4 4* 
Chemotherapy 
Adjuvant 12 13 
For Relapse 15 14 
Hormone Therapy 
Primary 1 0 
Adjuvant 6 6 
For Relapse 18 17 
Oophorectomy 
Surgical 1 1 
Radiation 2 1 




TABLE 13: NUMBER OF PATIENTS WITH METASTATIC DISEASE AT 
INITIATION OF THERAPY (NUMBER OF SITES OF DISEASE) 
Number of Sites of Disease Number 
A 
of Patients (Percentages 
AVM 
) 
0 0 0 
5 (20) 7 (25) 
1 5 7 
2 14 6 
18 (69) 17 (61) 
3 4 11 
4 0 2 




TABLE 14: NUMBER OF PATIENTS WITH METASTATIC DISEASE AT 
INITIATION OF THERAPY (SITES INVOLVED) 




Bone 19 (76) 20 (80) 
Li ver 8 (32) 7 (28) 
Lung 7 (28) 12 (48) 
Nodes 6 (24) 6 (24) 
Ski n 6 (20) 8 (32) 
PIeura 3 (12) 6 (24) 
Breast 3 (12) 4 (16) 
CNS 1 ( 4) 0 
Bone Marrow 1 ( 4) 1 ( 4) 
All others* 8 7 
Sites Include: chest wall, mediastinum, kidney, and subcutaneous 
mass. 

TABLE 15: RESPONSE TO THERAPY 
Number of Patients (Percentages) 
A AVM Total 






26 28 54 
0 0 0 
4 (15)* 8 (29)* 12 (22) 
22 (85) 20 (71) 42 (78) 
6 (27) 3 (15) 9 (21) 
16 (73) 17 (85) 33 (79) 
p value based on comparing the difference in groups shown using 
the Chi Square test 
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TABLE 16: SURVIVAL 
Median Survival p value* 
(months) 











2-3 7.59 .19 
>3 5.82 
Performance Status: 
Ambul atory 9.66 
.06 
Non-Ambulatory 6.87 
Disease-Free Interval (months) 
0-9 9.66 












* p value based on the difference comparing groups shown using the 
Mantel-Cox test 
** at initiation of study 
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TABLE 17: TIME TO PROGRESSION 
Median Time to Progression 
(months) 
p value* 
















Non-ambul atory 5.91 
Disease-free interval (months) 
0-6 3.02 












* p values based on the difference comparing groups shown using the 
Mantel-Cox test 
** at initiation of study 
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TABLE 18: NUMBER OF PATIENTS WITH METASTATIC DISEASE 
AT PROGRESSION 
(NUMBER OF SITES OF DISEASE) 
















5 24 (16) 1 4 (16) 
6 1 1 
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Sites of Disease Number of Patients (Percentages) 
A AVM 
Bone 13 (52) 16 (64) 
Liver 8 (32) 5 (20) 
Nodes 2 (8) 6 (24) 
Lung 7 (28) 8 (32) 
Skin 2 (8) 8 (32) 
PIeura 3 (12) 6 (24) 
Breast 2 (8) 3 (12) 
CNS 1 (4) 1 (4) 
Bone Marrow 1 (4) 2 (8) 
All others* 6 6 




TABLE 20: TOXICITY 
Type Adri amyci n Patients AVM Patients 
Patients Courses Patients Courses 
No. (%) No. (%) No. (%) No. {%) 
Cardiac 0 0 
Myelosuppression* 
WBC/ul3 
0-1000 1 ( 5) 1 ( 2) 5 (22) 11 (12) 
1001-2000 11 (52) 16 (30) 12 (52) 29 (33) 
2001-3000 6 (29) 22 (42) 3 (13) 33 (37) 
3001-4000 2 (10) 6 (11) 1 ( 4) 5 ( 6) 
>4000 2 ( 5) 8 (15) 2 ( 9) 11 (12) 
3 
Platelet count/ul 
<20,000 0 0 0 0 
20-50,000 2 (10) 2 ( 4) 1 ( 4) 3 ( 3) 
50-75,000 0 0 3 (13) 4 ( 5) 
75-100,000 3 (14) 3 ( 6) 4 (17) 5 ( 6) 
100-150,000 8 (38) 13 (25) 3 (13) 13 (15) 
>150,000 8 (38) 34 (65) 12 (52) 64 (72) 
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Figure 3. Survival for responders (R) versus non-responders 

















Months to Last Seen 
. Survival for all patients according to numbers of 
metastatic disease at initiation of treatment (L- 1 















Months to Last Seen 
at 
Survival for all patients according to perforaance 




























10 20 30 40 
Months to Last Seen 
Survival for all patients according to stage at 
s (1-Stage I; 2-Stage II; 3-Stage II; 4-Stage IV). 

y2 
Figure 7. Survival for all patients according to disease- 
free interval at initiation of treatment (L- 0-6 months; 


















Figure 8. Survival for all patients according to menopausal 
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Figure 10. Time to disease progression for all patient 
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Figure 13. Time to disease progression for all patients 
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